Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Hemostatic Ability of Thrombosomes® in Blood from Thrombocytopenic Patients Using the Total Thrombus Formation Analysis System (T-TAS) and Confocal Microscopy in Microfluidic Chambers

Sahar Samanbar, Juan Piñeyroa, Ana Belén Moreno-Castaño, Marc Pino, Sergi Torramade-Moix, Julia Martinez-Sanchez, Keith A. Moskowitz, Allan Alexander, Gines Escolar, Maribel Diaz-Ricart

Blood (2022) 140 (Supplement 1): 11242–11243.

https://doi.org/10.1182/blood-2022-169346

Published: 2022

Journal Articles

Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age

Blood (2021) 138 (Supplement 1): 3195.

https://doi.org/10.1182/blood-2021-147434

Published: 2021

Journal Articles

Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors with or without Prophylactic Treatment

Tammuella Chrisentery-Singleton, W Allan Alexander, Ahmad Al-Sabbagh, Daniel Bonzo, Michael U. Callaghan, Miguel A. Escobar, Adam Giermasz, Nikki Hirsh, Janna Journeycake, Sonia Nasr, Doris V. Quon, Michael Recht

Blood (2021) 138 (Supplement 1): 3201.

https://doi.org/10.1182/blood-2021-146247

Published: 2021

Journal Articles

Single 225μg/Kg Dose Treatment with Eptacog Beta (Factor VIIa, Recombinant) Results in Rapid Hemostasis in Joint Bleeds for Persons with Hemophilia Α or Β with Inhibitors: A PERSEPT1 Subset Analysis

Janna M. Journeycake, MD, Cedric Hermans, MDMRCP,PhD, Jonathan M. Ducore, MD MPH, Miguel A. Escobar, MD, Guy Young, MD, Michael Wang, MD, Doris Quon, MD PhD, W Allan Alexander, MD, Ian S Mitchell, PhD, Ahmad Al-Sabbagh, MD, Daniel Bonzo, PhD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136443

Published: 2020

Journal Articles

PERSEPT3: A Phase 3 Clinical Trial to Evaluate the Hemostatic Efficacy of Eptacog Beta (Recombinant Human FVIIa) in Perioperative Care in Subjects with Hemophilia Α or B with Inhibitors

Miguel A. Escobar, MD, Doris Quon, MD PhD, Cindy A. Leissinger, MD, James V Luck, Jr., MD, Ahmad Al-Sabbagh, MD, Daniel Bonzo, PhD, Ian S Mitchell, PhD, W Allan Alexander, MD, Cedric Hermans, MDMRCP,PhD

Blood (2020) 136 (Supplement 1): 34–36.

https://doi.org/10.1182/blood-2020-136448

Published: 2020

Journal Articles

Favorable Immunologic Response Profile to Recombinant Thrombin Application in Surgery: An Integrated Analysis of 8 Clinical Trials

William Chapman, MD, Kenneth Renkens, Jr., MD, Richard Gamelli, MD, FACS, Carlton Randleman, MD, Jeffrey Ballard, MD, W. Allan Alexander, MD

Blood (2008) 112 (11): 4088.

https://doi.org/10.1182/blood.V112.11.4088.4088

Published: 2008

Journal Articles

Favorable Immunologic Response to Recombinant Thrombin Application in Surgery among Subjects with Pre-Existing Antibodies to Bovine Thrombin.

Gregory Moneta, MD, Jeffrey Ballard, MD, Carlton Randleman, MD, Kenneth Renkens, Jr., MD, Neil Singla, MD, W. Allan Alexander, MD

Blood (2008) 112 (11): 3390.

https://doi.org/10.1182/blood.V112.11.3390.3390

Published: 2008

Journal Articles

Recombinant Thrombin Has a Superior Immunogenicity Profile Compared with Bovine Thrombin in a Well-Controlled, Randomized, Double-Blind, Phase 3 Study of Topically Applied Thrombins in Four Surgical Settings.

Linda A. Zuckerman, PhD, Susan Pederson, Dan R. Boster, Lisa Appesland, Dana M. Jackson, Erika Giste, Jonathan D. Newman, Allan Alexander, MD

Blood (2007) 110 (11): 3156.

https://doi.org/10.1182/blood.V110.11.3156.3156

Published: 2007

NARROW

Hemostatic Ability of Thrombosomes® in Blood from Thrombocytopenic Patients Using the Total Thrombus Formation Analysis System (T-TAS) and Confocal Microscopy in Microfluidic Chambers

Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age

Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors with or without Prophylactic Treatment

Single 225μg/Kg Dose Treatment with Eptacog Beta (Factor VIIa, Recombinant) Results in Rapid Hemostasis in Joint Bleeds for Persons with Hemophilia Α or Β with Inhibitors: A PERSEPT1 Subset Analysis

PERSEPT3: A Phase 3 Clinical Trial to Evaluate the Hemostatic Efficacy of Eptacog Beta (Recombinant Human FVIIa) in Perioperative Care in Subjects with Hemophilia Α or B with Inhibitors

Favorable Immunologic Response Profile to Recombinant Thrombin Application in Surgery: An Integrated Analysis of 8 Clinical Trials

Favorable Immunologic Response to Recombinant Thrombin Application in Surgery among Subjects with Pre-Existing Antibodies to Bovine Thrombin.

Recombinant Thrombin Has a Superior Immunogenicity Profile Compared with Bovine Thrombin in a Well-Controlled, Randomized, Double-Blind, Phase 3 Study of Topically Applied Thrombins in Four Surgical Settings.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only